Status:

TERMINATED

BOBBY™ Balloon Guide Catheter for Endovascular Treatment of Acute Ischemic Stroke

Lead Sponsor:

Microvention-Terumo, Inc.

Conditions:

Cerebrovascular Stroke

Eligibility:

All Genders

18-85 years

Brief Summary

Evaluation of the safety and performance of the BOBBY™ Balloon Guide Catheter (BGC) in patients with an acute ischemic stroke treatment, a sudden reduction or termination of the blood circulation of t...

Detailed Description

The main objective of the STRAIT study is to assess the performance of the mechanical thrombectomy using a BOBBY™ Balloon Guide Catheter (BGC) as adjunctive device for endovascular treatment of patien...

Eligibility Criteria

Inclusion

  • Patient is ≥ 18 and ≤ 85 years of age
  • Informed consent by the patient or legal authorized representative for data collection is obtained
  • Patient eligible for the mechanical thrombectomy treatment with adjunctive use of the BOBBY™ BGC
  • Patient presenting with an anterior circulation large-vessel occlusion of distal internal carotic artery (ICA ) through proximal M2 confirmed by computed tomograph angiography (CTA), magnetic resonance angiography (MRA), or digital subtraction angiography (DSA).
  • Core-infarct volume of Alberta Stroke Program Early CT Score (ASPECTS) ≥ 6 based on baseline CT or MR imaging
  • Treatment initiated (groin puncture) within 8 hours of symptom onset.
  • Patient with a pre-treatment National Institutes of Health Stroke Scale (NIHSS) score ≥5
  • Patient with no personal condition disabling the site to contact him/her at 90 days after procedure

Exclusion

  • Patient has evidence of cerebral ischemia in the posterior circulation
  • Patient presents severe unilateral or bilateral carotid artery stenosis requiring stent treatment during the procedure
  • Pregnancy or breastfeeding
  • Patient presents other serious medical illness (e.g., cancer) with estimated life expectancy of less than 3 months
  • Patient has a planned procedure that may cause non-compliance with the protocol or confound data interpretation
  • Patient is already participating in an investigational drug or device trial (change routine care of the patient)
  • Patient has evidence of intracerebral hemorrhage on initial imaging
  • Patient has a significant mass effect with midline shift

Key Trial Info

Start Date :

April 8 2022

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 30 2023

Estimated Enrollment :

171 Patients enrolled

Trial Details

Trial ID

NCT05361187

Start Date

April 8 2022

End Date

December 30 2023

Last Update

January 7 2025

Active Locations (9)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (9 locations)

1

Neuro-Kopf-Zentrum Klinikum rechts der Isar der Technischen Universität München

Munich, Bavaria, Germany

2

Martin Luther Universität Halle

Halle, Halle, Germany, 06120

3

Neurologische Klinik Abteilung für Neuroradiologie

Heidelberg, Germany

4

Klinikum Ingolstadt, Zentrum für Radiologie und Neuroradiologie

Ingolstadt, Germany